Read + Share
Giuliani J, Bonetti A. The cost-effectiveness of trastuzumab emtansine (T-DM1) in HER2-positive
metastatic breast cancer is supported by clinical evidence. Breast J 2020 Sep 13. doi: 10.1111/tbj.14024.
PMID: 32920921
|
 |
|
Giuliani J, Bonetti A. The cost-effectiveness of trastuzumab emtansine (T-DM1) in HER2-positive
metastatic breast cancer is supported by clinical evidence. Breast J 2020 Sep 13. doi: 10.1111/tbj.14024.
PMID: 32920921
|
|
|
|